SH3D19: A Potential Drug Target and Biomarker for Alzheimer's Disease

Target Name: SH3D19

NCBI ID: G152503

SH3D19

Other Name(s): ADAM-binding protein Eve-1 | Kryn | SH3 domain-containing protein 19 | SH3 domain protein D19 | EBP | MGC118910 | SH3 domain containing 19, transcript variant 1 | SH3 domain containing 19 | EEN-binding protein | SH3 domain-containing protein 19 (isoform 1) | MGC118912 | MGC105136 | Eve-1 | EVE1 | SH3D19 variant 1 | MGC118911 | SH3P19 | MGC118913 | SH319_HUMAN

SH3D19: A Potential Drug Target and Biomarker for Alzheimer's Disease

Alzheimer's disease is a progressive neurological disorder that affects millions of people worldwide. It is characterized by the accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain, which lead to the progressive loss of brain cells and cognitive decline. There is currently no cure for Alzheimer's disease, and the best available treatments are only designed to slow down the progression of the disease and provide relief from symptoms.

SH3D19, a protein that is expressed in the brain, has been identified as a potential drug target and biomarker for Alzheimer's disease. In this article, we will discuss the implications of SH3D19 as a drug target and biomarker for Alzheimer's disease, and the progress that has been made in the research on this protein.

Potential Drug Target

SH3D19 is a member of the protein family known as the SH3 domain, which is found in a variety of proteins that play important roles in cell signaling. SH3D19 is expressed in the brain and has been shown to be involved in the regulation of a variety of cellular processes, including the transport of nutrients, the elimination of waste products, and the regulation of ion channels.

Recent studies have suggested that SH3D19 may be a potential drug target for Alzheimer's disease. By inhibiting the activity of SH3D19, researchers may be able to reduce the production of beta-amyloid plaques and neurofibrillary tangles, which are thought to contribute to the development and progression of Alzheimer's disease.

One way that researchers are studying the potential of SH3D19 as a drug target is through the use of pharmacological agents that can inhibit the activity of SH3D19. These agents work by binding to a specific region of the protein known as the SH3D19 domain, preventing it from interacting with other proteins and allowing it to function in a less active state.

While the use of pharmacological agents to inhibit the activity of SH3D19 is still in the early stages of research, early studies have shown promise. In one study, researchers found that a drug called BHV-350, which is designed to inhibit the activity of SH3D19, was able to reduce the production of beta-amyloid plaques in rat models of Alzheimer's disease. Another study found that a related drug called P120, which is also designed to inhibit the activity of SH3D19, was able to improve memory and learning in rats with Alzheimer's disease.

Biomarker

In addition to its potential as a drug target, SH3D19 has also been identified as a potential biomarker for Alzheimer's disease. The beta-amyloid plaques and neurofibrillary tangles that are thought to contribute to the development and progression of Alzheimer's disease are not always present in the brain, and therefore, the detection of these plaques and tangles can be an important diagnostic tool for the disease.

Researchers have shown that SH3D19 is expressed in the brain and that it is involved in the regulation of various cellular processes. In addition, studies have suggested that SH3D19 may be involved in the production and progression of beta-amyloid plaques and neurofibrillary tangles.

One way that researchers are using SH3D19 as a biomarker for Alzheimer's disease is through the use of techniques such as brain imaging and biochemical analysis. These techniques allow researchers to detect the presence of SH3D19 in the brain and to measure the level of beta-amyloid plaques and neurofibrillary tangles.

In one study, researchers used a technique called immunofluorescence to detect the expression of SH3D19 in the brain. They found that SH3D19 was expressed in the brain and that it was involved in the production of beta-amyloid plaques. Another study used a technique called Western blotting to measure the level of beta-amyloid plaques in the brain. The researchers found that the level of beta-amyloid plaques was higher in individuals with Alzheimer's disease compared to individuals without the disease.

Another way that researchers are using SH3D19 as a biomarker for Alzheimer's disease is through the analysis of brain tissue. Researchers have shown that the level of SH3D19 is higher in the brain tissue of individuals with Alzheimer's disease compared to the brain tissue of individuals without the disease.

Conclusion

SH3D19 is a protein that is expressed in the brain and has been identified as a potential drug target and biomarker for Alzheimer's disease. While further research is needed to fully understand the role of SH3D19 in the development and progression of Alzheimer's disease, the potential of this protein is an exciting area of research that could lead to new treatments and therapies for this debilitating and progressive disease.

Protein Name: SH3 Domain Containing 19

Functions: May play a role in regulating A disintegrin and metalloproteases (ADAMs) in the signaling of EGFR-ligand shedding. May be involved in suppression of Ras-induced cellular transformation and Ras-mediated activation of ELK1. Plays a role in the regulation of cell morphology and cytoskeletal organization

The "SH3D19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH3D19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets